TickerTalks
Browse all tickers →
TickerTalks›$ARDX
ARARDX

Ardelyx, Inc.

Hot onWhy it's trendingX chatter spiked vs its recent normBacked by solid revenue growthPrice and volume picking up
$ARDX·$1.3B·Biotechnology·Healthcare
$5.20+1.5%YTD-11.0%1Y+15.0%
Mentions · last 7 days
2026-07-10: 32 posts2026-07-11: 22 posts2026-07-12: 29 posts2026-07-13: 119 posts2026-07-14: 95 posts2026-07-15: 149 posts2026-07-16: 124 posts575+36%
Price updated 6h ago·X counts updated 1d ago
ARARDX
$ARDXArdelyx, Inc.
$5.20+1.46%575 posts+36%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ARDX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-17

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

IBSRELA and Xphozah growth story at 24% of range with Q2 in three weeks and a $50M new term loan.

Ardelyx is a specialty biopharma with two commercial products — IBSRELA (constipation-predominant IBS) and Xphozah (hyperphosphatemia in dialysis patients). The equity has been range-bound on execution concerns even as revenue has grown well.

What the setup shows:

  • Growth is strong: Q1 revenue up 27% YoY to $94M, four-quarter stack is 8-33% — genuine acceleration off a low base.
  • Margins are choppy: gross margin 92%, operating margin -35% in Q1 (regression from Q4's +4%) — execution volatility is the concern.
  • The multiple looks cheap on FY27 numbers: consensus revenue is $544M with roughly break-even EPS — priced for continued growth to materialize.
  • Insider action: officer Laura Williams sold $490K on June 22 — modest cluster.
  • Debt drawdown of $50M under the Term F Loan (June 29) adds runway for the IBSRELA and Xphozah commercial ramp.
  • Position confirms the reset: 24% of 52-week range and 15% below the 200-day moving average — real digestion after the initial ramp.

The forward view: the August 3 Q2 print is the referee. A revenue beat with IBSRELA+Xphozah combined growth above 25% plus specific commentary on the Japanese Phase 3 Tenapanor pill-burden reduction paper's commercial implications restarts the coil upward. What keeps it stuck: an in-line growth print with continued operating-margin volatility. What breaks it lower: a specific IBSRELA generic-timing headline, or an FDA Form 483-related update that the CEO hasn't yet properly addressed (community concern).

Agrees with X sentimentThe bullish X read on 'best-in-class' framing and the $19 RJ target is directionally right. Our take agrees the fundamentals are compelling; the execution volatility (per the community's own bear voice) is the near-term risk.

What to watch: August 3 Q2 earnings and IBSRELA+Xphozah growth commentary; a specific IBSRELA generic-timing headline or FDA Form 483 update would break the coil the wrong way.

On the calendar: 2026-08-03 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment9 posts analyzed · as of 2026-07-07

Ardelyx bulls anchor to a $1.26B market cap versus roughly $600M annualized revenue run rate, a fresh Japanese Phase 3 post-hoc paper showing Tenapanor reduces phosphate-binder pill burden, and RJ maintaining a Strong Buy with a $19 target. Best-in-class narrative dominates: 'the drug works and is best in class,' 400M+ revenue last year, growth trajectory strong. The bear voice cites poor execution (ARDX and TMDX called 'two of the worst stocks in the market' by frustrated longs) and a CEO who did not properly address the Form 483, but the dominant tone is undervalued vs fundamentals.

Read the AI verdict + X sentiment for $ARDX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Commercial biotech with tenapanor approved to block phosphate absorption in dialysis patients with hyperphosphatemia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ARDX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $ARDX

Partial — Commercial biotech with tenapanor approved to block phosphate absorption in dialysis patients with hyperphosphatemia; the GLP-1 pipeline bifurcation and ADA oral formulation competition is a secondary rather than primary near-term earnings catalyst.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-23.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-9.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-8.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-38.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
91.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$-0.15$-0.13-15.4%
Q4 2025Feb 19, 2026$0.02$0.020.0%
Q3 2025Oct 30, 2025$-0.00$-0.06+93.3%
Q2 2025Aug 4, 2025$-0.08$-0.13+38.5%
Next earningsMon, Aug 3·consensus EPS $-0.05

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$94.5M+27.5%94.9%-34.7%$-0.15$-32.3M
Q4 FY25$125.2M+7.8%90.6%4.1%$-0.00$20.6M
Q3 FY25$110.3M+12.3%95.6%4.2%$-0.00$209K
Q2 FY25$97.7M+33.4%86.7%-14.7%$-0.08$-26.0M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$543.6M$538.7M – $549.8M-$0.06-$0.13 – $0.028
FY27$739.6M$698.4M – $771.0M$0.49$0.28 – $0.648
FY28$983.7M$983.7M – $983.7M$1.16$0.72 – $1.508
FY29$1.3B$1.2B – $1.3B$1.82$1.72 – $1.917
FY30$1.4B$1.4B – $1.5B$2.25$2.12 – $2.357

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.26%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-13.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 237.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.605-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 15Michael RaabCEO41.7K sh$211KSellJun 18Laura A WilliamsChief Patient Officer81.9K sh$490KSellJun 15Michael RaabCEO41.7K sh$236KSellMay 21Reilly Joseph JamesSee Remarks3.7K sh$23KSellMay 21John E BishopSee Remarks2.3K sh$14KSellMay 21Brady James ParkerChief Human Resources Officer1.8K sh$12KSellMay 21Foster Eric DuaneChief Commercial Officer8.0K sh$50KSellMay 21Laura A WilliamsChief Patient Officer7.0K sh$44KSellMay 21Mike KelliherChief Business Officer7.2K sh$45KSellMay 21Michael RaabCEO54.7K sh$343K
1–10 of 24
+ 20 other (13 awards · 7 exempts) in window

See when $ARDX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial debt obligationJul 28-K — Item 2.03: Material debt obligation
AI summary

Ardelyx, Inc. (ARDX) drew down $50.0 million under a new Term F Loan tranche on June 29, 2026, under its existing loan and security agreement with SLR Investment Corp. as collateral agent — a facility first established in February 2022 and amended multiple times through 2024. This creates a new direct financial obligation per Item 2.03. The draw provides additional runway for the commercial-stage pharma company; specific use of proceeds and updated total debt load are not disclosed in the excerpt.

8-KOfficer or director changeJun 178-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Ardelyx, Inc. filed an 8-K (Items 5.02, 5.07) dated June 16, 2026, reporting both a director/officer change and shareholder vote results from its annual meeting. The excerpt is cover-page only with no vote tallies or officer names disclosed. These are routine governance disclosures; the 5.07 vote results are administrative unless contested proposals failed.

8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

ARDX reported period ending 2026-04-30 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

3New insider — initial holdingsApr 223
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for ARDX on 2026-04-22, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2036 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsApr 33
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for ARDX on 2026-04-03, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2036 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KPress release / Reg FDFeb 198-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 11 other (5 13Gs · 3 proxys · 1 10-Q · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transactionfool.com·24d agoArdelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reachmarketbeat.com·44d agoArdelyx to Participate at the Jefferies Global Healthcare Conference 2026globenewswire.com·60d agoArdelyx: Low Price, But High Implied Valuationseekingalpha.com·71d agoArdelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetingsglobenewswire.com·72d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport